₹ 1.2 Cr
Volume Transacted
(Jan 3, 2025)
40.3 K
Stocks Traded
(Jan 3, 2025)
Last Updated on: Jan 06, 2025
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
03 Jan 2025 | 297.55 | 303.2 | 303.2 | 296.5 |
02 Jan 2025 | 298 | 304.85 | 307.1 | 296.95 |
01 Jan 2025 | 304.7 | 301.05 | 308.15 | 296.7 |
31 Dec 2024 | 296.7 | 285.7 | 298.15 | 285.7 |
30 Dec 2024 | 287.35 | 294 | 294.85 | 285.65 |
27 Dec 2024 | 293.6 | 290.2 | 296.55 | 290.2 |
26 Dec 2024 | 290.15 | 296.95 | 299.65 | 288.95 |
24 Dec 2024 | 293.65 | 294 | 299.5 | 292.55 |
23 Dec 2024 | 293.55 | 303.15 | 303.15 | 292.5 |
20 Dec 2024 | 303.65 | 316.8 | 323.7 | 275.25 |
Date | Price (₹) |
---|---|
03 Jan 2025 | 297.55 |
02 Jan 2025 | 298 |
01 Jan 2025 | 304.7 |
31 Dec 2024 | 296.7 |
30 Dec 2024 | 287.35 |
27 Dec 2024 | 293.6 |
26 Dec 2024 | 290.15 |
24 Dec 2024 | 293.65 |
23 Dec 2024 | 293.55 |
20 Dec 2024 | 303.65 |
Marksans Pharma receives USFDA approval for Loratadine Tablets
Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Applica...
22 Nov 2024 12:47
Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA
The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and u...
22 Nov 2024 13:23
Marksans Pharma gains after Q2 PAT rises 16% YoY to Rs 97 cr
The firm stated that growth was witnessed across all key markets, led by US and followed b...
12 Nov 2024 13:22
Marksans Pharma to declare Quarterly Result
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 Novembe...
23 Oct 2024 17:41
Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules
Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketin...
21 Aug 2024 20:00
Marksans Pharma's Verna unit successfully completes USFDA inspection
Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR...
20 Aug 2024 14:37
Unlimited trading starting at just Rs. 249*